Sanofi Acquires Dynavax for $15.50 per Share, 39% Premium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18h ago
0mins
Source: PRnewswire
- Acquisition Agreement: Sanofi announced its acquisition of Dynavax for $15.50 per share in cash, totaling approximately $2.2 billion, representing a 39% premium, which will enhance Sanofi's market position in adult immunization.
- Vaccine Portfolio: The acquisition includes Dynavax's marketed adult hepatitis B vaccine HEPLISAV-B and the shingles vaccine candidate (Z-1018) in development, enriching Sanofi's vaccine offerings to meet growing public health needs.
- Market Opportunity: With nearly 100 million adults in the U.S. unvaccinated against hepatitis B and shingles affecting one in three adults, the acquisition positions Sanofi to better address these unmet health needs and increase market share.
- Transaction Timeline: The deal is expected to close in Q1 2026, with Sanofi funding the acquisition through available cash resources, demonstrating its long-term commitment and strategic investment in the vaccine market.
DVAX
$15.38+Infinity%1D
Analyst Views on DVAX
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 21.00 USD with a low forecast of 11.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 11.130
Low
11.00
Averages
21.00
High
32.00
Current: 11.130
Low
11.00
Averages
21.00
High
32.00
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
